LJH685 is potent pan-RSK inhibitor that targets RSK N-terminal kinase domain (NTKD) ATP-binding site (IC50/[ATP] = 6 nM/5 μM/RSK1, 5 nM/20 μM/RSK2, 4 nM/10 μM/RSK3). LJI308 effectivelfy inhibits MAPK pathway-dependent cancer growth (EC50 values of 0.73 μM/MDA-MB-231 and 0.79 μM/H358) by reducing the phosphorylation level of cellular Y-box binding protein-1 (YB1) Ser102 (EC50 = 0.2-0.3 μM; MDA-MB-231 and H358), but not that of ribosomal S6 protein (S6RP) S235/236.
NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA, 95111733, human lung (bronchoalveolar), Not specified
assay
≥98% (HPLC)
assay
≥98% (HPLC)
assay
≥95% (HPLC)
assay
-
form
powder
form
powder
form
lyophilized powder
form
-
Quality Level
100
Quality Level
100
Quality Level
-
Quality Level
-
storage temp.
2-8°C
storage temp.
−20°C
storage temp.
−20°C
storage temp.
−196°C
solubility
DMSO: 2 mg/mL, clear (Warmed)
solubility
DMSO: 5 mg/mL, clear (warmed)
solubility
-
solubility
-
color
white to beige
color
white to beige
color
-
color
-
Classe di stoccaggio
11 - Combustible Solids
Che succede?
WGK 3
Punto di infiammabilità (°F)
Not applicable
Punto di infiammabilità (°C)
Not applicable
Scegli una delle versioni più recenti:
Certificati d'analisi (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.